Cardiff Oncology Prices Oversubscribed $40 Million Underwritten Registered Direct Offering
December 10, 2024 07:20 ET
|
Cardiff Oncology, Inc.
SAN DIEGO, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF) (“Cardiff Oncology” or the “Company”), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop...
Cardiff Oncology Reports Third Quarter 2024 Results and Provides Business Update
November 07, 2024 16:05 ET
|
Cardiff Oncology, Inc.
- Published positive Phase 2 trial results of onvansertib in combination with FOLFIRI and bev in second-line KRAS mutant mCRC in the peer-reviewed Journal of Clinical Oncology - - Initial data...
Cardiff Oncology to Report Second Quarter 2024 Results and Provide Business Update
August 01, 2024 16:05 ET
|
Cardiff Oncology, Inc.
SAN DIEGO, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of...
Cardiff Oncology to Present at the Jefferies Healthcare Conference
May 29, 2024 16:05 ET
|
Cardiff Oncology, Inc.
SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of...
Cardiff Oncology Reports First Quarter 2024 Results and Provides Business Update
May 02, 2024 16:05 ET
|
Cardiff Oncology, Inc.
- In RAS-mutated mCRC, clinical data from ONSEMBLE trial, and preclinical data presented at AACR, demonstrated strong efficacy signal in bev naïve patients and support ongoing first-line RAS-mutated...
Cardiff Oncology to Report First Quarter 2024 Results and Provide Business Update
April 25, 2024 16:05 ET
|
Cardiff Oncology, Inc.
- Management will hold a conference call on Thursday, May 2 at 4:30 p.m. ET/1:30 p.m. PT - SAN DIEGO, April 25, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a...
Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study
April 08, 2024 16:05 ET
|
Cardiff Oncology, Inc.
RAS-mutated mCRC – In RAS-mutated mCRC, novel preclinical finding demonstrates onvansertib inhibits the tumor’s ability to adapt to hypoxia resulting in a significant decrease in both tumor...
Cyclacel Pharmaceuticals Announces at-the-market $7 Million Strategic Investment by Fundamental Investor Acorn Bioventures
December 22, 2020 08:00 ET
|
Cyclacel
- Strategic investment from single biotech-focused institutional investor - - Enables clinical development of both fadraciclib and CYC140 in hematological malignancies and solid tumors - BERKELEY...